Dave A Ricks

Obesity is the root disease for over 200 chronic diseases, it impacts more than 1 in 7 people on the planet and more options are needed. Science doing a good job here making the case for much more innovation in Obesity care. It’s still very early, yet we can see the impact that is possible. Lilly doing our part to lead on new mechanisms, more convenient, more durable and more accessible weight loss solutions for the world.

Obesity management medications: The way forward | Science science.org/doi/10.1126/sc…

I’ll take that bet.

In other news, US projected to save billions expanding access to Obesity care according to independent group at USC 👇🏻@DrOz @DrOzCMS

medrxiv.org/content/10.648…

Proud of TEAM Lilly, we are executing well. While 2026 is setting up to be a year to remember I am even more excited about our future…
- 4 Incretin projects in phase 3 now, raising the bar of what’s possible in weight loss, reducing side effect burden and radically expanding indications caused by obesity. We are building the tools to solve overweight and obesity, and hopefully the 200 terrible diseases it causes, at a global scale.
-Rapidly expanding Cancer portfolio in B cell driven disease, Breast and Ovarian cancer as well as Lung and more.
- Treating or preventing the worst neurodegenerative diseases we know
- Unlocking the potential of one and done therapy for common diseases like lymphomas, wet AMD, childhood deafness and even something as common as high LDL cholesterol.
The future of biomedical technology is going to amaze.

@LizClaman Great conversation, building in America 🇺🇸, the incredible future of drug discovery 💊 and our next generation weight loss therapy ⚛️!